Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study (European Urology)

Treatment of high-risk metastatic castration-sensitive prostate cancer with abiraterone acetate and prednisone (AAP) + androgen deprivation therapy demonstrates a significant depth of prostate-specific antigen response strongly correlated with long-term outcomes of radiological progression-free survival and overall survival, which may be clinically meaningful in the management of AAP treatment in this setting.